The efficacy and safety of elbasvir and grazoprevir for hepatitis C virus genotype 1 in a real clinical setting

DOI IR Web Site
  • Miyasaka Akio
    Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan Department of Gastroenterology, Iwate Prefectural Ninohe Hospital
  • Yoshida Yuichi
    Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan Department of Gastroenterology, Iwate Prefectural Ninohe Hospital
  • Suzuki Akiko
    Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan
  • Takikawa Yasuhiro
    Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan

Bibliographic Information

Other Title
  • 実臨床におけるGenotype1型C型肝炎に対するエルバスビル・グラゾプレビルの治療効果と安全性

Search this article

Abstract

We aimed to evaluate the efficacy and safety of 12-week treatment with elbasvir (EBR) and grazoprevir (GZR) in patients with hepatitis C virus (HCV) genotype (GT) 1 infection in a real-world setting. A total of 67 patients with chronic hepatitis or compensated hepatic cirrhosis and GT 1 HCV infection were treated with EBR＋GZR for 12 weeks and followed for 12 weeks after the completion of treatment. A sustained virological response (SVR12) was defined as undetectable HCV RNA 12 weeks after completing treatment. The efficacy and safety of this 12-week treatment regimen were analyzed. Among the 67 patients (male, n=39; female, n=28), 23 (34%) had compensated liver cirrhosis, while only 1 (1%) had experienced treatment failure with another DAA treatment regimen. The overall SVR12 rate was 97% (95% confidence interval 0.896 – 0.996), and the rate was not significantly affected by age, sex, liver stiffness, Fib-4 index, or eGFR at baseline. No severe adverse events occurred. The most frequent adverse event was increased alanine aminotransferase concentration in 4 patients (6%). The efficacy and safety of 12 weeks of EBR+GZR for patients with chronic hepatitis or compensated hepatic cirrhosis and HCV GT 1 infection was confirmed in this study.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top